A novel liver-on-a-chip model can be used to study immune cell interactions in liver cancer and test promising new therapies.

Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a ...

Research Impact is a series that pulls back the curtain of IU Research, showcasing the faculty creating, innovating and ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, mature data from its ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients.

Surgical oncologists at MD Anderson Cancer Center at Cooper recently became the first in New Jersey to treat a patient with ...

Maui County residents can participate online in a Sept. 18 University of Hawaiʻi Cancer Center “Quest for a Cure” event to ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...